With cancer accounting for nearly 10 million deaths in 2020 and 28 million new cases of cancer expected every year by 2040, the speed at which new treatments reach patients must accelerate.
We published the first edition of our Digital Patient Profile catalog last week, to give the industry access to a granular breakdown of patient populations for 28 key disease indications, derived from analysis of patient data in the industry’s largest clinical trial database. This includes 11 oncology indications and other prevalent diseases including Alzheimer’s, COVID-19 and Crohn’s disease.
Each patient profile offers a statistical view of patient attributes for each indication – such as demographics, including ethnicity, comorbidities, outcomes and concomitant medications, among many other key variables associated with patient safety and efficacy analysis, specific to that indication. Based on data from more than 60 million patients from 195 countries and 485,000 curated clinical trials and amendments, Digital Patient Profiles enable robust program and trial design and execution simulation helping sponsors to predict trial outcomes and measure risk factors at a trial level and patient level.
Each Digital Patient Profile helps clinical researchers to take a data-led program and study design and execution approach taking into account changes in standards of care and patient pathways. For instance, the typical patient for breast cancer has become younger, with clinical trials now including more women of childbearing age. Phesi analysis found that since 2014, the number of women younger than 60 years old in breast cancer trials has increased from 30% to around 80%. This changing profile brings with it new considerations for trial design such as potential fertility and pregnancy concerns, which means a comprehensive patient view is vital.
Misalignment between the patient population a protocol is trying to target and the actual patient population recruited in a clinical trial following that protocol leads to enrollment delay, numerous avoidable protocol amendments, and worse yet, clinical trial termination. In our working with clients, we have repeatedly proven that DPP can materially improve protocol design, leading to successful innovative medicines meeting dire needs from patients.
Using Digital Patient Profiles to design patient-centric trials and optimize the clinical development process will help sponsors manage costs, reduce cycle times, and accelerate the commercialization of new medicines. The Phesi Trial Accelerator platform can create detailed profiles for over 4000 indications and simulate clinical trial outcomes, which has the potential to fundamentally transform drug development across all therapeutic areas including oncology.
Access the full Digital Patient Profile catalog here: https://info.phesi.com/dpp